Thermo Fisher ScientificTMO
Market Cap: $234B
About: Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
Employees: 122,000
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
15% more repeat investments, than reductions
Existing positions increased: 1,037 | Existing positions reduced: 904
0% less funds holding
Funds holding: 2,471 [Q1] → 2,467 (-4) [Q2]
2% less first-time investments, than exits
New positions opened: 157 | Existing positions closed: 161
1.2% less ownership
Funds ownership: 89.87% [Q1] → 88.68% (-1.2%) [Q2]
6% less capital invested
Capital invested by funds: $199B [Q1] → $187B (-$12.1B) [Q2]
10% less funds holding in top 10
Funds holding in top 10: 124 [Q1] → 111 (-13) [Q2]
35% less call options, than puts
Call options by funds: $950M | Put options by funds: $1.47B
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Wells Fargo Brandon Couillard 36% 1-year accuracy 4 / 11 met price target | 10%upside $670 | Overweight Initiated | 27 Aug 2024 |
TD Cowen Dan Brennan 61% 1-year accuracy 17 / 28 met price target | 8%upside $658 | Buy Maintained | 25 Jul 2024 |
Raymond James Andrew Cooper 89% 1-year accuracy 17 / 19 met price target | 8%upside $660 | Outperform Maintained | 25 Jul 2024 |
RBC Capital Conor McNamara 39% 1-year accuracy 15 / 38 met price target | 9%upside $664 | Outperform Maintained | 25 Jul 2024 |
Stifel Daniel Arias 58% 1-year accuracy 11 / 19 met price target | 1%upside $615 | Buy Maintained | 25 Jul 2024 |
Financial journalist opinion
Based on 6 articles about TMO published over the past 30 days